PsyPost on MSN15h
Single-dose psilocybin therapy shows promise for veterans with treatment-resistant depression
A recent study published in the Journal of Affective Disorders suggests that a single dose of psilocybin may offer hope for U ...
Vikram Purohit Recommends ‘Buy’ for COMPASS Pathways Amid Strategic Adjustments and Promising COMP360 Program
Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target of ...
Money Talks News on MSN1d
Psychedelic Mushrooms Show Promise in Treating Mental Health Conditions
Psychedelic mushrooms, containing the active ingredient psilocybin, have shown remarkable potential in treating various mental health conditions, including treatment-resistant depression. Leading ...
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
Enveric Biosciences expands its patent portfolio with five new U.S. patents, supporting treatments for depression, anxiety ...
NJBIZ1d
Legislators weigh change in law over ‘magic mushroom’ compound
State lawmakers are considering a bill that would legalize production and use of psilocybin as a mental health treatment in ...
Compass Pathways: No Near-Term Fix For Struggling Psychedelic Therapy Pioneer
Compass Pathways is advancing pivotal trials to test psilocybin's impact on treatment-resistant depression. See why I rate ...
MedPage Today2d
Esketamine Also Effective Without Adjunctive Antidepressant
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine nasal spray (Spravato) monotherapy ...
Indian Defence Review3d
A Portable Electrostimulation Device Could Make Severe Depression Treatment Possible from Home
A groundbreaking study reveals that a portable electrostimulation device could revolutionize the treatment of severe ...
psychiatryadvisor.com4d
Esketamine for TRD Improves Depressive Symptoms, Regardless of TMS History
Esketamine for TRD demonstrated efficacy in reducing depressive symptoms and did not significantly differ based on TMS treatment history.
Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Compass Pathways plc has exciting developments in treating treatment-resistant depression with the innovative COMP360. Click ...
Compass Pathways' Losses Widen in Q3
With its clinical trials at a pivotal stage, Compass Pathways is burning more cash, but reported a slightly ...
Transcranial direct current stimulation at home may lead to significant reductions in depression symptoms
In such cases, patients may be prescribed neuromodulation therapy, which modulates brain activity in order to reduce ...